Search NASA⌕ Search

SEARCH · Search NASA

Results for “RADIUM 225”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 records

CPsuperH2.3: an Updated Tool for Phenomenology in the MSSM with Explicit CP Violation

We describe the Fortran code CPsuperH2.3, which incorporates the following updates compared with its predecessor CPsuperH2.0. It implements improved calculations of the Higgs-boson masses and mixing including stau contributions and finite threshold effects on the tau-lepton Yukawa coupling. It incorporates the LEP limits on the processes e^+e^-->H_iZ,H_iH_j and the CMS limits on H_i->@t@?@t obtained from 4.6 fb^-^1 of data at a center-of-mass energy of 7 TeV. It also includes the decay mode H_i->Z@c and the Schiff-moment contributions to the electric dipole moments of Mercury and Radium 225, with several calculational options for the case of Mercury. These additions make CPsuperH2.3 a suitable tool for analyzing possible CP-violating effects in the MSSM in the era of the LHC and a new generation of EDM experiments. Program summary: Program title: CPsuperH2.3 Catalogue identifier: ADSR_v3_0 Program summary URL:http://cpc.cs.qub.ac.uk/summaries/ADSR_v3_0.html Program obtainable from: CPC Program Library, Queen's University, Belfast, N. Ireland Licensing provisions: Standard CPC licence, http://cpc.cs.qub.ac.uk/licence/licence.html No. of lines in distributed program, including test data, etc.: 24058 No. of bytes in distributed program, including test data, etc.: 158721 Distribution format: tar.gz Programming language: Fortran77. Computer: PC running under Linux and computers in Unix environment. Operating system: Linux. RAM: 32 MB Classification: 11.1. Does the new version supersede the previous version?: Yes Catalogue identifier of previous version: ADSR_v2_0 Journal reference of previous version: Comput. Phys. Comm. 180(2009)312 Nature of problem: The calculations of mass spectrum, decay widths and branching ratios of the neutral and charged Higgs bosons in the Minimal Supersymmetric Standard Model with explicit CP violation have been improved. The program is based on renormalization-group-improved diagrammatic calculations that include dominant higher-order logarithmic and threshold corrections, b-quark and @t-lepton Yukawa-coupling resummation effects and improved treatment of Higgs-boson pole-mass shifts. The couplings of the Higgs bosons to the Standard Model gauge bosons and fermions, to their supersymmetric partners and all the trilinear and quartic Higgs-boson self-couplings are also calculated. Also included are a full treatment of the 4x4 (2x2) neutral (charged) Higgs propagator matrix together with the center-of-mass dependent Higgs-boson couplings to gluons and photons, and an integrated treatment of several B-meson observables. The new implementations include the EDMs of Thallium, neutron, Mercury, Deuteron, Radium, and muon, as well as the anomalous magnetic moment of muon, (g_@m-2), the top-quark decays, improved calculations of the Higgs-boson masses and mixing including stau contributions, the LEP limits, and the CMS limits on H_i->@t@t@?. It also implements the decay mode H_i->Z@c and includes the corresponding Standard Model branching ratios of the three neutral Higgs bosons in the array GAMBRN(IM,IWB = 2,IH). Solution method: One-dimensional numerical integration for several Higgs-decay modes and EDMs, iterative treatment of the threshold corrections and Higgs-boson pole masses, and the numerical diagonalization of the neutralino mass matrix. Reasons for new version: Mainly to provide the full calculations of the EDMs of Thallium, neutron, Mercury, Deuteron, Radium, and muon as well as (g_@m-2), improved calculations of the Higgs-boson masses and mixing including stau contributions, the LEP limits, the CMS limits on H_i->@t@t@?, the top-quark decays, H_i->Z@c decay, and the corresponding Standard Model branching ratios of the three neutral Higgs bosons. Summary of revisions: Full calculations of the EDMs of Thallium, neutron, Mercury, Deuteron, Radium, and muon as well as (g_@m-2). Improved treatment of Higgs-boson masses and mixing including stau contributions. The LEP limits. The CMS limits on H_i->@t@t@?. The top-quark decays. The H_i->Z@c decay. The corresponding Standard Model branching ratios of the three neutral Higgs bosons. Running time: Less than 1.0 s.

72 PHYSICS OF ELEMENTARY PARTICLES AND FIELDS↗

Nuclear Data Sheets for A = 225

The evaluators present in this publication spectroscopic data and level schemes from radioactive decay and nuclear reactions for all isobars with mass number A = 225.

73 NUCLEAR PHYSICS AND RADIATION PHYSICS↗

Accelerator Production of {sup 225}Ac For Alpha-Immunotherapy

{sup 225}Ac has tremendous potential for the treatment of metastatic cancer due to the four alpha-particles emitted during its decay to stable {sup 209}Bi. Additionally, it is one of the few alpha-emitters being considered for clinical trials. The anticipated {sup 225}Ac demand for these trials is expected to far exceed the annual worldwide supply of approximately 1,000 mCi/yr. Consequently, the DOE Office of Science has funded investigations into accelerator-based production of {sup 225}Ac. Existing {sup 232}Th(p,x){sup 225}Ac cross section data indicate that up to 480 mCi/day of {sup 225}Ac could be created by bombarding a thick target of natural thorium with 100 MeV protons at the Los Alamos Isotope Production Facility. To verify these predictions, experiments are underway at the Los Alamos Neutron Science Center to measure the {sup 232}Th(p,x){sup 225}Ac production cross sections for protons in the energy range 40-200 MeV, and at 800 MeV. For 800 MeV protons, preliminary results indicate that the {sup 225}Ac production cross section is 12.4{+-}0.6 mb and the {sup 225}Ra production cross section is 3.2{+-}0.2 mb. Moreover, preliminary results suggest that the {sup 227}Ac production cross section is 16{+-}1 mb. Experiments to measure these same cross sections at proton energies below 200 MeV are planned for the last half of calendar year 2010.

43 PARTICLE ACCELERATORS↗

Atomic electric dipole moment induced by the nuclear electric dipole moment: The magnetic moment effect

We have considered a mechanism for inducing a time-reversal violating electric dipole moment (EDM) in atoms through the interaction of a nuclear EDM d{sub N} with the hyperfine interaction, the ''magnetic moment effect''. We have derived the operator for this interaction and presented analytical formulas for the matrix elements between atomic states. Induced EDMs in the diamagnetic atoms {sup 129}Xe, {sup 171}Yb, {sup 199}Hg, {sup 211}Rn, and {sup 225}Ra have been calculated numerically. From the experimental limits on the atomic EDMs of {sup 129}Xe and {sup 199}Hg we have placed the following constraints on the nuclear EDMs, |d{sub N}({sup 129}Xe)|<1.1x10{sup -21}|e|cm and |d{sub N}({sup 199}Hg)|<2.8x10{sup -24}|e|cm.

74 ATOMIC AND MOLECULAR PHYSICS↗

Recommended Nuclear Data for the Production of Selected Therapeutic Radionuclides

Increasing interest in the treatment of human disease by means of targeted radionuclide-based therapies requires an accurate understanding of achievable yields and quantification of realisable degrees of purity. Important studies within a more extensive Coordinated Research Project of the International Atomic Energy Agency (IAEA CRP) have included in-depth assessments and evaluations of all available measured cross-section data for ten nuclear reactions leading to the formation of 131 Cs, 131 Ba, 225 Ac, 225 Ra, 227 Th, 227 Ac, 230 U and 230 Pa for various on-going and proposed therapeutic applications in nuclear medicine. Equivalent studies were also undertaken of possible reactions to produce the 178W /low-spin 178m Ta generator system that has been clinically applied in diagnosis by means of SPECT - these particular cross-section studies and recommendations are included in this paper for completeness. All available measured data have been critically reviewed and assessed to produce statistically consistent datasets. Selected datasets have been fitted by a least-squares method with Padé approximations of variable order to evaluate the production cross sections and corresponding uncertainties. New measurements have been made in some instances, and reported data have been adjusted to accommodate new nuclear decay or monitor reaction data which altered the original reported quantities adversely. Insufficient measured data are available in many cases to permit a reliable evaluation of cross sections, and these instances are discussed. Finally, recommended therapeutic radionuclide production reaction data and their uncertainties are available on the Web page of the IAEA Nuclear Data Section at www-nds.iaea.org/radionuclides/ and also at the IAEA medical portal www-nds.iaea.org/medportal/.

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTAN↗

Progress toward an EDM measurement in {sup225}Ra.

Permanent electric dipole moments (EDMs) in atoms or molecules are a signature of time-reversal and parity violation and represent an important window onto physics beyond the Standard Model. We are developing a next generation EDM search based on laser-cooled and trapped {sup 225}Ra atoms. Due to octupole deformation of the nucleus, {sup 225}Ra is predicted to be two to three orders of magnitude more sensitive to T-violating interactions than {sup 199}Hg, which currently sets the most stringent limits in the nuclear sector. We will discuss progress toward realizing a first EDM measurement for {sup 225}Ra.

72 PHYSICS OF ELEMENTARY PARTICLES AND FIELDS↗

Production of Ra225 precursor for Ac225/Bi213 generators. Final CRADA Report.

Russian subcontractors shipped two small deliveries of Ra225 to PNNL for evaluation. The activity was close to the requisite amount in the subcontract. The first labeled properly; the second did not. This showed that the Russians could supply Ra225 to the US; however they proved unable to meet future demands for larger amounts of activity. The US DOE attempts to get Ra225 from Russian should be terminated; the Russians, under Rosatom, are not interested in this business.

07 ISOTOPE AND RADIATION SOURCES↗

Observation of the distribution of nuclear magnetization in a molecule

Precise experimental control and interrogation of molecules and calculations of their structure are enriching the investigation of nuclear and particle physics phenomena. Molecules containing heavy, octupole-deformed nuclei, such as radium, are of particular interest. Here, we report precision laser spectroscopy measurements and theoretical calculations of the structure of the radioactive radium monofluoride molecule 225 Ra 19 F. Our results reveal fine details of the short-range electron-nucleus interaction, indicating the high sensitivity of this molecule to the distribution of magnetization, within the radium nucleus. Here, these results provide a stringent test of the description of the electronic wave function inside the nuclear volume, highlighting the suitability of these molecules for investigating subatomic phenomena.

Nuclear structure↗

Metal Oxide Sorbents for the Separation of Radium and Actinium

The inorganic, normal-phase sorbents alumina, titania, and zirconia were evaluated and screened for the separation of Ba, La, 228 Ra, 228 Ac, and 212 Pb in a dilute acid matrix. The results show that the sorbents are capable of fractionating the ions between pH 1 and 8. A stationary zirconia column was used to isolate Ba from La and Ra from Ac/Pb; elution profiles of each separation are presented. The utility and implications of these sorbents are discussed with respect to large-scale production of 225 Ac from radium targets.

37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CH↗

Developing Inorganic Resins for Radium and Actinium Generators and Purifications

The inorganic, normal-phase sorbents alumina, titania, and zirconia were evaluated and screened for the separation of Ba, La, 228 Ra, 228 Ac, and 212 Pb in a dilute acid matrix. The results show that the sorbents are capable of fractionating the ions between pH 1–8. Acetate and total metal ion concentrations were experimentally evaluated as factors that could affect retention using La and Ba surrogates. Pseudo-second order rate constants were derived and the uptake of La was determined to be endothermic. A stationary zirconia column was used to isolate Ba from La and Ra from Ac/Pb; elution profiles of each separation are presented. The utility and implications of these sorbents are discussed with respects to large-scale production of 225 Ac from radium targets. This work was published in 2020 and in 2022.

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEA↗

Microfluidics-based separation of actinium-225 from radium-225 for medical applications

Separation of 225 Ra (t 1/2 = 15 d) from its daughter isotope 225 Ac (t 1/2 = 10 d) is necessary to obtain pure 225 Ac for cancer alpha-therapy. In this study, microscale separation of 225 Ra from its daughter 225 Ac using BioRad AG50X4 cation exchange resin was achieved with good reproducibility across microdevices, and ≥90% purity was achieved for 225 Ac, which is comparable to conventional chromatography. These results indicate the potential for greater use of microfluidics for biomedical radiochemistry. The modularity of the system and its compatibility with different resins allows for quick and easy adaptation to the various needs of a separation campaign.

29 ENERGY PLANNING, POLICY, AND ECONOMY↗

The application of poorly crystalline silicotitanate in production of 225 Ac

Actinium-225 ( 225 Ac) can be produced from a Thorium-229/Radium-225 ( 229 Th/ 225 Ra) generator, from high/low energy proton irradiated natural Thorium or Radium-226 target. Titanium based ion exchanger were evaluated for purification of 225 Ac. Poorly crystalline silicotitanate (PCST) ion exchanger had high selectivity for Ba, Ag and Th. 225 Ac was received with trace amounts of 227 Ac, 227 Th and 223 Ra, and the solution was used to evaluate the retention of the isotopes on PCST ion exchanger. Over 90% of the 225 Ac was recovered from PCST, and the radiopurity was >99% (calculated based on 225 Ac, 227 Th, and 223 Ra). The capacity of the PCST inorganic ion exchange for Barium and 232 Th was determined to be 24.19 mg/mL for Barium and 5.05 mg/mL for Thorium. PCST ion exchanger could separate 225 Ac from isotopes of Ra and Th, and the process represents an interesting one step separation that could be used in an 225 Ac generator from 225 Ra and/or 229 Th. Capacity studies indicated PCST could be used to separate 225 Ac produced on small 226 Ra targets (0.3–1 g), but PCST did not have a high enough capacity for production scale Th targets (50–100 g).

43 PARTICLE ACCELERATORS↗

Simultaneous Separation of Actinium and Radium Isotopes from a Proton Irradiated Thorium Matrix

A new method has been developed for the isolation of 223,224,225 Ra, in high yield and purity, from a proton irradiated 232 Th matrix. We report an all-aqueous process using multiple solid-supported adsorption steps including a citrate chelation method developed to remove >99.9% of the barium contaminants by activity from the final radium product. Moreover, we developed a procedure involving the use of three columns in succession, and the separation of 223,224,225 Ra from the thorium matrix was obtained with an overall recovery yield of 91 ± 3%, average radiochemical purity of 99.9%, and production yields that correspond to physical yields based on previously measured excitation functions.

38 RADIATION CHEMISTRY, RADIOCHEMISTRY, AND NUCLEA↗

Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations

Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for cancer treatment. When coupled with monoclonal antibodies, peptides, small molecules, or nanoparticles, the excellent cytotoxic capability of α-particle emissions has generated a strong interest in exploring targeted α-therapy in the pre-clinical setting and more recently in clinical trials in oncology. Multiple obstacles have been overcome by researchers and clinicians to accelerate the development of targeted α-therapies, especially with the recent improvement in isotope production and purification, but also with the development of innovative strategies for optimized targeting. Numerous studies have demonstrated the in vitro and in vivo efficacy of the targeted α-therapy. Radium-223 ( 223 Ra) dichloride (Xofigo®) is the first α-emitter to have received FDA approval for the treatment of prostate cancer with metastatic bone lesions. There is a significant increase in the number of clinical trials in oncology using several radionuclides such as Actinium-225 ( 225 Ac), Bismuth-213 ( 213 Bi), Lead-212 ( 212 Pb), Astatine ( 211 At) or Radium-223 ( 223 Ra) assessing their safety and preliminary activity. Finally, this review will cover their therapeutic application as well as summarize the investigations that provide the foundation for further clinical development.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Examination of Ac-225 production from Ra-226 using fast reactor JOYO

In this study, the authors investigated the method of producing the radionuclide Ac{sup 225} used for targeted alpha therapy (TAT). Currently, Ac{sup 225} is mainly generated from ORNL's Th{sup 229} generator, and the annual production amount is limited to about 63 GBq, and methods for generating it using accelerators are under development in each country. The method using an accelerator has the advantage of being able to generate Ac{sup 225} from a small amount of target nuclides with high efficiency but has the disadvantage of not being able to irradiate a large amount of target nuclides at once due to the small irradiation area. Therefore, the authors investigated a method to generate Ac{sup 225} by neutron irradiation of Ra{sup 226} as a target nuclide using the experimental fast reactor JOYO, which has abundant neutrons and a large loading region. Irradiation of Ra{sup 226} with fast neutrons causes a (n, 2n) reaction to generate Ra{sup 225}, and then decay to produce Ac{sup 225}. In addition, although harmful Ac{sup 227} is also produced at the same time by the (n,γ) reaction, first of all the actinium isotope is chemically separated and eliminated. Since the remaining Ra{sup 225} collapses and Ac{sup 225} is produced, pure Ac{sup 225} can be extracted by performing chemical separation again. As a result of the analysis, 1 g of Ra{sup 226} is irradiated with JOYO for 60 days, and milking is performed 4 times every 17.5 days. By doing these three times a year, it was found that about 50 GBq of Ac{sup 225} was generated. (authors)

07 ISOTOPE AND RADIATION SOURCES↗

Production of Actinium-225 via High Energy Proton Induced Spallation of Thorium-232

The science of cancer research is currently expanding its use of alpha particle emitting radioisotopes. Coupled with the discovery and proliferation of molecular species that seek out and attach to tumors, new therapy and diagnostics are being developed to enhance the treatment of cancer and other diseases. This latest technology is commonly referred to as Alpha Immunotherapy (AIT). Actinium-225/Bismuth-213 is a parent/daughter alpha-emitting radioisotope pair that is highly sought after because of the potential for treating numerous diseases and its ability to be chemically compatible with many known and widely used carrier molecules (such as monoclonal antibodies and proteins/peptides). Unfortunately, the worldwide supply of actinium-225 is limited to about 1,000mCi annually and most of that is currently spoken for, thus limiting the ability of this radioisotope pair to enter into research and subsequently clinical trials. The route proposed herein utilizes high energy protons to produce actinium-225 via spallation of a thorium-232 target. As part of previous R and D efforts carried out at Argonne National Laboratory recently in support of the proposed US FRIB facility, it was shown that a very effective production mechanism for actinium-225 is spallation of thorium-232 by high energy proton beams. The base-line simulation for the production rate of actinium-225 by this reaction mechanism is 8E12 atoms per second at 200 MeV proton beam energy with 50 g/cm2 thorium target and 100 kW beam power. An irradiation of one actinium-225 half-life (10 days) produces {approx}100 Ci of actinium-225. For a given beam current the reaction cross section increases slightly with energy to about 400 MeV and then decreases slightly for beam energies in the several GeV regime. The object of this effort is to refine the simulations at proton beam energies of 400 MeV and above up to about 8 GeV. Once completed, the simulations will be experimentally verified using 400 MeV and 8 GeV protons available at Fermi National Accelerator Laboratory. Targets will be processed at Argonne National Laboratory to separate and purify the actinium-225 that will subsequently be transferred to NorthStar laboratory facilities for product quality testing and comparison to the product quality of ORNL produced actinium-225, which is currently the industry standard. The test irradiations at FNAL will produce 1-20 mCi per day which is more than sufficient for quantitative evaluation of the proposed production process. The beneficial outcome of this effort will be a new production route for actinium-225 that does not use or require any uranium-233 materials owned by DOE or use any radium-226 as an irradiation target but can supply the medical community's needs for actinium-225 now and in the future.

07 ISOTOPE AND RADIATION SOURCES↗